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Abstract   
In a cross-sectional study of 296 perinatally HIV-infected children and adolescents from Zimbabwe, 
individuals with the top tertile of CMV-Specific Immunoglobulin G titre had an increased odds of 
chronic lung disease (odds ratio 3.33; 95% confidence interval 1.37-8.85; p = 0.010). 
 





















Widespread use of combination antiretroviral therapy (cART) has increased the number of children 
with perinatal HIV infection (PHIV) surviving into adolescence. However, there is growing evidence 
that despite cART, HIV infection in children is associated with multisystem chronic comorbidities and 
concomitant disability (1). This is likely driven by chronic systemic immune activation, which CMV co-
infection can exacerbate.  
Studies from sub-Saharan Africa have shown that chronic lung disease (CLD) is a common 
comorbidity affecting about a third  of PHIV children aged 10 years or more (2). Radiological findings 
are consistent with constrictive obliterative bronchiolitis (COB, as the main cause (3). COB is typically 
characterised by ongoing airway inflammation, resulting in progressive tissue remodelling, fibrosis of 
the small airways and lung function decline (4). Pediatric COB in the southern hemisphere mostly 
occurs as a sequela of severe lower respiratory tract infections (LRTIs) (4). As a common LRTI in 
infants with HIV, the association of cytomegalovirus (CMV) with chronic lung disease is of particular 
interest. CMV is a common cause of pneumonitis in infants with PHIV and has been shown to 
exacerbate experimental pulmonary fibrosis in murine models (5). In individuals with HIV, CMV co-
infection contributes to immune activation and inflammation-related morbidities, even in the 
context of virological suppression of HIV by cART (6). 
Recent studies from our group described a high prevalence of CMV DNA in the plasma of children 
and adolescents with PHIV from Zimbabwe  (7). In this population, CMV viral load above 1000 
copies/ml was associated with reduced forced vital capacity (FVC), lower CD4 T-cell counts and 
stunting. In the present cross-sectional study, we sought to determine the associations between 
both CMV-specific immunoglobulin G (IgG) titre alongside CMV plasma viremia with CLD as defined 
by airflow obstruction in a cross -sample of the participants from the BREATHE clinical trial (8).  
 
Methods 
We conducted a cross-sectional case-control study nested within the Bronchopulmonary Function in 
Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children (BREATHE) 
trial (8)  (ClinicalTrials.gov, NCT02426112). The trial recruited PHIV children and adolescents aged 
between 6-19 years old from Malawi and Zimbabwe, who had been taking cART for at least six 
months, with a diagnosis of chronic lung disease, defined as forced expiratory volume in one second 
(FEV1) z-score <-1 with lack of reversibility with salbutamol. Z-scores were generated using Global 
Lung Function Initiative reference standards. Individuals with tuberculosis (TB), acute respiratory 
tract infections or potentially fatal conditions at time of screening were excluded. A comparison 
group matched for age (6-12 and 13-19 years) and duration on cART (6 months to <2 years and >2 
years) was recruited from HIV clinic attendees with FEV1 z-score >0 and no chronic cough in the past 
3 months. First thaw cryopreserved baseline plasma samples for participants recruited in Harare 


















Laboratory Methods  
CMV-specific IgG levels were measured using the Abcam Anti-Cytomegalovirus (CMV) IgG Human 
ELISA kit as per manufacturer’s instructions. Samples were run in duplicate and mean values per 
participant are reported in International Units (IU) per ml. CMV-specific IgG levels were split into 
tertiles for the entire cohort and the CLD group.  
Total viral nucleic acids were extracted from 200 µL plasma using the QIAamp MinElute Virus Spin Kit 
(Qiagen, Hilden, Germany). 100µL of total viral nucleic acids were eluted and immediately stored 
at −80°C for subsequent testing. CMV detection was performed by quantitative polymerase chain 
reaction (PCR) using the RealStar CMV PCR kit v1.0 (Altona Diagnostics, Hamburg, Germany) as per 
the manufacturer’s instructions. Samples were run on the QuantStudio 3 Real-Time PCR system in 
duplicate (Applied Biosystems, CA).  Samples were repeated when technical replicas were no  
concordant for CMV presence. CMV viral load is reported in international units (IU)/ml.  
Statistical Methods 
Data were analysed in R Studio (Version 1.1.383). The mean and standard deviation was used to 
describe continuous variables and categorical variables were described with proportions. Differences 
between study groups were assessed by Mann-Witney U Tests or Chi-square tests as appropriate.  
Weight-for-age and height-for-age z-scores were calculated using British 1990 Growth Reference 
Curves. Z-scores less than -2 represented wasting and stunting respectively. Chronic lung disease 
was defined as per the BREATHE protocol (FEV1 z-score <-1) (8). 
The association of CMV-specific IgG tertile and CLD was assessed by logistic regression. Linear 
regression was used to assess the association between both CMV measures and FEV1 z-score. 
Participant age, sex, height-for-age z-score, previous TB treatment, HIV viral load and cART regimen 
were included as covariates in all models. A sensitivity analysis where enrolment into the CLD group 
was defined by FEV1 z-score <-1.64 was performed.  
Ethics 
Consent from individuals within the BREATHE study was sought from the guardian and age-
appropriate assent from the participant (for those aged <18 years). Ethical approval for this sub-
study was granted by the Medical Research Council of Zimbabwe. 
Results  
A total of 241 cases and 55 controls were included in this study. A higher proportion of cases were 
female, reported previous treatment for TB, were stunted and wasted then the control group 
(Supplementary table 1). Cases had a lower mean CD4 T-cell count than the controls. There was no 
evidence of significant difference in HIV viral load or duration of cART between groups 
(Supplementary Table 1). Across both groups the median (IQR) time on cART was 6.44 (4.15-8.42). 
The mean (standard deviation (SD)) CMV-specific IgG level was higher in the group with CLD than the 
group without (48.4 ± 12.1 vs 39.7 ± 13.0, p=<0.001). 100% of participants were CMV seropositive. 


















Top and mid tertiles of CMV-specific IgG titre were significantly associated with increased odds of 
CLD compared to the bottom tertile (top-tertile OR = 3.33; 95% CI= 1.37-8.85; p=0.010 and mid-
tertile OR= 2.17; 95% CI =1.60-4.55; p=0.036)) (Table 1).  CMV-Specific IgG as a continuous measure 
was also associated with increased odds of CLD (OR=1.05; 95% CI= 1.02-1.08; p=0.003). CMV DNA in 
plasma was significantly associated with reduced FEV1 z-score in cases (Coefficient ± SE = -0.30 ± 
0.14; p=0.028). Neither tertile nor CMV specific-IgG as a continuous measure were not associated 
with FEV1 z-score in the case group. In all analyses, duration of ART had no significant effect model 
results. CMV-specific IgG titre negatively correlated with CD4 T-cell count in both groups. Spearman 
rank correlation coefficients are presented in Supplementary Figure 1. Only the association between 
CMV specific IgG and FEV1 z-score is modified in the sensitivity analysis (Supplementary table 2).   
 
Discussion 
As a common cause of LRTI in HIV-infected infants, we hypothesized that CMV may be associated 
with CLD in the PHIV population (9). Our results show that top tertile CMV-specific IgG titre is 
associated with obstructive lung disease, supporting previous associations between CMV presence in 
plasma and reduced lung function (7). These findings contribute to our understanding of the 
association of CMV with HIV-1-associated airway disease in Sub-Saharan Africa. 
Infant coinfection of CMV and HIV leads to rapid disease progression and often pneumonitis, which 
alongside systemic inflammation may drive chronic lung disease (9). CMV-specific IgG titre can be 
used as a putative marker of lifelong CMV exposure and increases with impaired control of the virus. 
CMV Specific IgG is associated with elevated immune activation markers and with the CD45RA+ 
CD27- T-cell memory phenotype, indicative of multiple rounds of restimulation (10,11). High 
antibody levels could represent increased exposure to CMV antigens before cART, or persistent B-
cell in activation individuals with CLD. CMV viremia in the plasma of study participants is likely to 
indicate viral reactivation. The complete absence of CMV DNA in the control group is consistent with 
increased lifelong exposure to CMV within the case group. 
This study is limited by its cross-sectional and associative design. Levels of CMV-specific IgG were 
generally high in the cohort, reflecting the overall burden of CMV infection in sub-Saharan Africa. 
Prevalence of CMV viremia and CMV viral load in the plasma of participants was lower than recent 
reports, likely explained by more stable cART use in BREATHE compared to previous studies (7). As a 
result, the number of individuals with detectable CMV in the plasma was small. Further work is 
required to address whether CMV is a marker of impaired cellular immunity and/or the driver of the 
pathology described (12). Lower respiratory tract samples would strengthen these findings.  
In conclusion, we provide further evidence that CMV co-infection in HIV-infected individuals is 
associated with CLD. We extend previous findings, reporting associations between CMV specific IgG 
titre and CLD. HIV associated comorbidities, such as CLD, represent a growing burden of disease in 
PHIV adolescents on stable cART. These results underline the need for future studies to assess 
causality, and suggest that available CMV-specific antiviral drugs such as valganciclovir may be 
beneficial within this population of PHIV individuals at the time of acute infection or reactivation. 
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Legend for table:  
Table 1: Factors associated with CLD in the case-control study (logistic regression) and factors 
associated with FEV-1 in children with CLD (linear regression).  
*Linear regressions are performed in the CLD group only. **All multivariable analysis includes age, 
sex, height for age z-score, previous TB treatment, cART regime and HIV viral load as confounding 
variables. Tertile comparisons are compared to lowest tertile within the group compared. CMV DNA 
presence in plasma could not be included in logistic regression models due to no cases in the control 



















Variable  CLD logistic regression in whole cohort (n=296) FEV1 z-score linear regression in CLD cases* (n=241) 
 Odds Ratio (CI, P) 
univariable 
Adjusted Odds Ratio (CI, 
P) ** 
Coefficient ± SE, P univariable Coefficient ± SE, P 
multivariable** 
Middle tertile CMV 





0.09 ± 0.12, p= 0.445 -0.05 ± 0.11, p=0.655 
Top tertile CMV 
specific IgG 




-0.24 ± 0.11 p=0.032 -0.09 ± 0.12, p= 0.431  




-0.01 ± <0.01, p=0.032 <-0.01 ± <-0.01, p= 
0.461 
CMV DNA Presence in 
Plasma 
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